qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection
and quantification of RNA targets and is being utilized increasingly in novel clinical …

The appropriate management of haematological disorders must rely on a precise and long-
term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data …

Point mutations within the ABL kinase domain of the BCR-ABL gene are associated with
clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML). To obtain more …

Background: Imatinib mesylate is a drug used in treating chronic myeloid leukemia (CML). It
induces apoptosis and inhibits cell proliferation. This study aimed to evaluate hematologic …

This retrospective analysis investigated the prognostic value of monitoring the response to
imatinib using peripheral blood (PB) samples and the impact of the response on outcome in …

Both the tumour suppressor, p16, and the helix-loop-helix transcription factor, Id1, have
been assigned roles in tumour growth in general and appear to be involved in …

Abstract Objectives Among Chronic Myeloid Leukemia (CML) patients treated with Tyrosine
Kinase Inhibitor (TKI-imatinib-nilotinib), some showed a suboptimal response. Based on …

The diagnosis of haematological malignancies has begun to emerge as a distinct
pathological discipline in the United Kingdom. This has been driven by the recommendation …

The development of new powerful applications and the improvement in fabrication
techniques are promising an explosive growth in lab-on-chip use in the upcoming future. As …

Most patients with a chronic phase of chronic myeloid leukemia (CML) treated with imatinib
mesylate achieve a cytogenetic remission, but in the majority, residual disease is detectable …